SNY/REGN cut Praluent’s US list price 60%—matching AMGN’s 2018 action on Repatha: https://www.prnewswire.com/news-releases/regeneron-and-sanofi-offer-praluent-alirocumab-at-a-new-reduced-us-list-price-300792853.html